Key Highlights
- Cathie Wood’s ARK Invest acquired 42,126 Cerebras Systems shares valued at approximately $11.8 million via ARKK and ARKW ETFs on May 22
- The firm simultaneously purchased 105,810 Twist Bioscience shares for $6.2 million and 25,029 Bullish shares worth $900,000
- ARK divested 1,859 Advanced Micro Devices shares totaling $835,787, extending its week-long pattern of position reduction
- Cerebras received expedited S&P index approval effective May 25, skipping the typical 12-month eligibility window
- The AI chip manufacturer derives 86% of total revenue from merely two Abu Dhabi-based customers, creating significant concentration vulnerability
Cathie Wood’s ARK Invest executed several notable portfolio adjustments on Friday, May 22, 2026, with the most significant being a substantial investment in Cerebras Systems, a recently public artificial intelligence semiconductor company.
The investment firm acquired 42,126 Cerebras shares distributed across its ARKK and ARKW exchange-traded funds. The combined transaction value reached approximately $11.8 million. This purchase represents a continuation of ARK’s accumulation strategy in Cerebras from previous weeks.
Cerebras completed its initial public offering on May 14. The shares were originally priced at $185, surged to $350 at market open, and momentarily touched $385 during debut trading. By week’s end, the stock had stabilized around the $280 mark.
The company’s market capitalization approached $100 billion at its zenith. This impressive valuation emerged despite Cerebras reporting $510 million in annual revenue and $87.9 million in net profit for the fiscal year 2025.
Investor demand for the IPO exceeded available shares by a factor of 20. Such overwhelming interest signals strong market conviction in the company’s technological capabilities beyond its present financial metrics.
Cerebras’s Unique Technology Approach
Cerebras manufactures semiconductors using an unconventional method that preserves an entire silicon wafer as a single unit rather than dividing it into multiple smaller chips. This produces a unified processor approximately the dimensions of a dinner plate. According to the company, this architecture eliminates latency issues associated with connecting numerous separate chips.
This innovative design has captured the attention of investors positioning themselves for the next generation of AI computing infrastructure.
Expedited S&P Inclusion and Market Impact
On May 19, S&P Dow Jones announced that Cerebras would join its index through an accelerated process, taking effect May 25. The company circumvented the conventional 12-month seasoning requirement by satisfying specific market capitalization criteria.
Index membership triggers mandatory share purchases by passive funds tracking the S&P. This mechanism generated additional buying momentum following the disclosure.
GuruFocus assigns Cerebras a GF Score of 42 out of 100. The company’s financial strength receives a rating of 3 out of 10, indicating its nascent development stage.
A primary concern among market analysts involves revenue concentration. Two clients connected to Abu Dhabi represent 86% of the company’s aggregate revenue. Any disruption to these relationships would pose significant challenges for immediate replacement.
Available regulatory filings indicate no insider transactions by company executives during the preceding three-month period.
Additional ARK Portfolio Activity
ARK simultaneously purchased 105,810 Twist Bioscience shares valued at $6.2 million, demonstrating ongoing commitment to the biotechnology sector. The firm also accumulated 25,029 Bullish shares distributed across three ETFs, totaling approximately $900,000.
Regarding divestments, ARK liquidated 1,859 Advanced Micro Devices shares for $835,787 through its ARKW ETF. This transaction extends an ongoing trend of reducing its AMD allocation throughout the past week.





